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Abstract: Nonalcoholic fatty liver disease (NAFLD) includes a wide spectrum of liver conditions ranging from simple 
steatosis to nonalcoholic steatohepatitis (NASH) and advanced hepatic fibrosis. Taking into account that NAFLD shares 
many common risk factors with cardiovascular diseases, it is evident that NAFLD may promote to increased 
cardiovascular morbidity and mortality. 
Cumulative evidence suggests that NAFLD is linked to atherosclerosis, coronary artery disease, obesity, type 2 diabetes, 
and also predicts the clustering of risk factors for cardiovascular diseases. 
To our opinion, the role of NAFLD in the prediction of cardiovascular risks should be investigated for coronary artery 
disease (CAD) prognosis assessment 
This review focuses on the pathophysiologic relationships between NAFLD and cardiovascular diseases, subclinical and 
clinical cardiovascular manifestations in NAFLD. 
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INTRODUCTION 
Non-alcoholic fatty liver disease (NAFLD) is the 
most common hepatic disease in developed countries 
and represents not only liver related morbidity and 
mortality but also affecting other systems and 
regulatory pathways. 
The main focus of the NAFLD related extrahepatic 
pathologies has involved cardiovascular diseases and 
type 2 diabetes mellitus. Several studies confirm that 
patients affected by NAFLD have a higher risk of 
developing cardiovascular (CV) abnormalities and 
events [1, 2]. Studies may provide pathophysiologic 
evidence of relationships between NAFLD and 
development of cardiovascular complications, 
particularly metabolic, systemic vascular inflammation, 
hypercholesterolemia. Based on clinical research data 
the development of CVD is substantially influenced by 
NAFLD and NASH (non-alcoholic steatohepatitis), and 
its prevention may provide an indication to therapy of 
NAFLD and NASH. 
PATHOGENESIS AND RESULTS OF STUDIES 
Several clinical investigations provide evidence of 
NAFLD pathogenetic role in the development of 
cardiovascular diseases and relationships between 
NAFLD and subclinical CAD. Both in cross-sectional 
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and in follow-up studies, NAFLD has been shown to be 
an independent risk factor for the presence or future 
development of increased intima-media thickness and 
of impaired flow-mediated vasodilatation; the presence 
of carotid atherosclerotic lesions; an increased 
coronary artery calcium score on cardiac computed 
tomography; and abnormal coronary flow reserve as a 
marker for impaired coronary microcirculation. These 
data are confirmed by report of recent meta-analysis of 
27 studies [3]. Recently in a cohort of 755 consecutive 
otherwise healthy adult men [4, 5] also presented a 
strong and independent association between NAFLD 
and carotid artery inflammation, which is reflecting 
plaque vulnerability evaluated by F-fluorodeoxyglucose 
positron emission tomography [6]. The review of 
several studies shows that NAFLD is an independent 
predictor for clinical CAD, measured as the severity of 
the atherosclerotic lesions on coronarography or the 
occurrence of fatal and number of non-fatal CAD 
events [7, 8]. At the same time, few studies did not 
confirm the independent relationship of NAFLD with 
incident CAD or showed it to be confined to patients 
with NAFLD who concomitantly met the diagnosis of 
the metabolic syndrome [9]. Several studies also 
showed a link between NAFLD and alterations in 
cardiac metabolism, structure and hemodynamic 
function, such as myocardial insulin resistance and 
mitochondrial adenosine triphosphate (ATP) 
production, cardiac steatosis, myocardial hypertrophy 
and left ventricular diastolic dysfunction, not attributable 
to concomitant diabetes, obesity or arterial 
hypertension. The severity of these cardiac 
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abnormalities correlated with the severity of the 
NAFLD. 
Interestingly, recent data have shown that NAFLD is 
also independently linked with cQT interval 
prolongation, a major risk factor for ventricular 
arrhythmias and sudden cardiac death, which might 
explain in part the increased CV mortality associated 
with NAFLD [10].  
Several data showed that NAFLD promotes to the 
progression of diastolic heart failure (independently of 
hypertension) and aortic valve sclerosis [11]. 
Pathogenetic role of NAFLD influences to the 
progression of atherosclerosis and several 
cardiovascular pathologies include abnormalities of 
myocardial metabolism and fat accumulation, 
increased incidence of atrial fibrillation [12] and 
prolongation of QT interval [13], obesity with left 
ventricular diastolic dysfunction [14], aortic valve 
sclerosis [15], NAFLD, type 2 diabetes mellitus, 
metabolic syndrome and cardiovascular diseases 
share many metabolic features and risk factors, leading 
to the theory that they belong to a complex multi-
system disease with several organ manifestation and 
complex interplay between the different mechanisms, 
with multiple bidirectional cause-effect relationships. 
There are several mechanisms interplaying in 
pathogenesis of cardiovascular complications in 
NAFLD, where each of them may contribute 
independently to the progression of cardiovascular 
morbidily. So far as the liver is a key organ in both 
glucose and lipid homeostasis, it is not surprising that 
evidence is accumulating that NAFLD plays a role in 
the development of type 2 diabetes mellitus and the 
metabolic syndrome, which are by themselves are 
cardiovascular risk factors. NAFLD has indeed been 
shown to contribute to the development of diabetes 
mellitus. Several studies with NAFLD confirmed by 
ultrasound or liver enzymes, have shown that NAFLD 
proceeds and predict the future development of T2DM 
independent of obesity and other factors of the 
metabolic syndrome [16]. 
It is clear also that NAFLD may be associated with 
an atherogenic lipid profile. In NAFLD, production of 
triglyceride-rich VLDL particles is increased [17]. Insulin 
normally inhibits adipose tissue lipolysis (the main 
source of FFA flux to the liver for hepatic triglycerides 
synthesis) and hepatic VLDL secretion, both of which 
are hence increased in association with hepatic and 
adipose tissue insulin resistance [18]. Subsequently, 
HDL-cholesterol levels fall and LDL-cholesterol levels 
rise, both of which are highly atherogenic conditions. 
Endothelial dysfunction has been shown to be an 
early event in the development of atherosclerosis. 
Several studies have recently highlighted that insulin 
resistance at the endothelial level occurs early in the 
development of NAFLD and is already present after a 
few days of high fat feeding, when steatosis develops 
but inflammation seems still to be absent [19]. 
In addition to macrovascular changes, NAFLD is 
also associated with microvascular complications, such 
as nephropathy, retinopathy, and neuropathy. 
Accumulating evidence has demonstrated that NAFLD 
is associated with increased prevalence and incidence 
of chronic kidney disease, defined as presence of 
microalbuminuria, overt proteinuria or an estimated 
glomerular filtration rate (GFR) <60 ml/min/1.73 m2, in 
both non-diabetic and diabetic individuals [20]. 
Hepatic insulin resistance has been shown to be 
increased in severe steatosis and this occurs due to 
endothelial damage. Furthermore, steatosis also 
induces structural abnormalities of liver vasculature, 
contributing to the associated increase in intrahepatic 
resistance. Angiogenic factors have been shown to 
play a role in the intrahepatic vascular changes in 
cirrhosis and are also studied in NASH. Altered levels 
of angiogenic factors, well documented in the 
atherosclerosis [21], have been observed in the 
peripheral blood of patients with NASH. 
Adiponectin, which is lower in patients with NAFLD, 
is another factor that might represent a link between 
NAFLD and CVD. Adiponectin has anti-atherogenic 
properties and directly affects endothelial function. It 
also stimulates circulating angiogenic cells. 
Inflammatory cytokines, which are activated in 
NAFLD and NASH may play pathogenic role to the 
systemic vascular inflammation and proatherogenic 
effects [22]. 
Recent studies suggest the NAFLD/NASH is 
characterized by inflammation of the liver which may 
secrete pro-inflammatory, pro-fibrogenic, and anti-
fibrinolytic substances, including fetuin-A, tumor 
necrosis factor-alpha and plasminogen activator 
inhibitor-1, all causing kidney injury. The above 
mentioned meta-analysis also found that even mild 
renal impairment may promote NAFLD generation, 
within a vicious cycle, with cardiovascular diseases and 
metabolic consequences suggesting that kidney 
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diseases may contribute to the pathogenesis of NAFLD 
[23, 24].  
Although all these mechanisms are plausible links 
between the liver affected by NAFLD and the 
development of CVD, no studies to date have 
scientifically proven a cause-effect relationship. Most 
probably, several mechanisms are concomitantly 
present, and might substantially differ between 
patients. Further study is therefore needed to gain 
mechanistic insights into the pathophysiology of the 
NAFLD-CVD axis, with an individualized preventive 
and therapeutic as the ultimate goal. 
Figure 1 illustrates the pathophysiological relationships 
between NAFLD end cardiovascular complications 
TREATMENT 
Currently there is no approved pharmacological 
treatment for NAFLD. Although it can be hypothesized 
that improving NAFLD reduces the risk of CVD, there is 
currently limited data on potential changes in the risk of 
CVD in relation to the success of NAFLD treatment. 
Interestingly, two recent studies on the effects of statins 
on CV events demonstrated a significantly reduced CV 
event rate in those patients with baseline elevation of 
liver tests (used as a surrogate marker for the presence 
of NAFLD) as well as significantly improved liver tests 
in one of the studies [25]. The cardio-protective effect 
of statins was less pronounced in patients with normal 
liver tests at baseline. Glitazones also improve CV risk, 
but it is unclear to what extent this can be attributed to 
their beneficial effect on NAFLD. Furthermore, as 
outlined previously, it is not clear whether the risk of 
CVD is increased in all subtypes of NAFLD. Therefore, 
no evidence-based recommendation can be formulated 
at present. 
Currently it is recommended to screen for NAFLD in 
every patient with risk factors for CVD or established 
CVD and to screen for NAFLD in every patient with 
NAFLD. Patient should be treated accordingly with life-
style modification. This recommendation is debated, as 
there are no data on cost-effectiveness and no 
pharmacological treatment when NAFLD is diagnosed. 
CONCLUSION 
The prevalence of NAFLD is growing worldwide and 
NAFLD is a widespread disease because of epidemics 
of obesity, diabetes, and metabolic syndrome. NAFLD 
also has an increased risk of multisystem affection 
particulary cardiovascular syste, with increased 
morbidity and mortality.  
 
Figure 1: represents the pathophysiological relationships between NAFLD end cardiovascular complications. 
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The review of pathophysiologic interrelationships 
between NAFLD and cardiovascular complications and 
results of several clinical studies and their meta-
analyses provide further evidence that NAFLD 
represents an independent risk factor to the 
development of atherosclerosis and CAD, metabolic 
syndrome, with increased cardiovascular mortality. 
Several clinical states such as metabolic syndrome 
with atherogenic profile, increased intima-media 
thickness, high inflammatory markers in blood plasma 
may serve as clinical indicators of NAFLD 
cardiovascular unfavorable effects and may contribute 
to cardiovascular diseases progression and increased 
cardiovascular risk. 
A number of prognostic markers are commonly 
used in clinical practice for cardiovascular risk 
estimation including other systemic abnormalities on 
the Global Registry of Acute Coronary Events 
(GRACE) score, on the Thrombolysis in Myocardial 
Infarction (TIMI) risk score. In all these scores there is 
no liver pathology related clinical or laboratory scaled 
data. Taking into consideration that the NAFLD has 
several overlapping relationships with cardiovascular 
diseases and endothelial dysfunction, the role of 
NAFLD in the prediction of cardiovascular risks should 
be investigated for CAD assessment. Further studies 
with large population of patients for the assessment of 
major cardiovascular events of CAD and NAFLD 
patients, including acute myocardial infarction, may 
provide evidence in elucidating of this both liver related 
pathology and problem. Early detection of NAFLD and 
NASH, advanced fibrosis may lead to the treatment of 
cardiovascular risk factors with lifestyle measures and 
multifactorial drug intervention. 
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